BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

CHMP backs Ebola vaccine, targeted cancer therapies  EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...
BioCentury | May 30, 2020
Finance

Ovarian cancer data help Mersana raise $152M to top off $9B month of follow-ons

Catalyzed by interim data unveiled Wednesday from a Phase I trial of its lead product, Mersana raised $152 million late Thursday to advance its clinical and preclinical antibody-drug conjugates. Mersana Therapeutics Inc. (NASDAQ:MRSN), which also...
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | May 29, 2020
Product Development

CEPI funding fuels Novavax vaccine trial start, ex-U.S. manufacturing land grab

After enrolling the first volunteers in a Phase I/II trial for its COVID-19 vaccine, Novavax acquired a Czech company that will provide manufacturing capacity outside the U.S., helping the biotech to meet its commitment to...
BioCentury | May 28, 2020
Product Development

Daily Chart: TIGIT pipeline heats up

With last week’s data from Genentech, the next-generation checkpoint target TIGIT has started to out-shine its peers. At least 11 TIGIT inhibitors are coming up behind Genentech’s tiragolumab in the pipeline. The Roche unit released...
BioCentury | May 27, 2020
Product Development

FDA takes on COVID-19, plus ASCO’s breakthroughs: a BioCentury podcast

The latest edition of the BioCentury This Week PODCAST covers a lot of ground -- from the new roles FDA’s Janet Woodcock and Peter Marks are taking on in the race to develop COVID-19 countermeasures,...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | May 19, 2020
Politics, Policy & Law

New faces for COVID-19’s next phase, ASCO’s hot topics: a BioCentury podcast

In the latest edition of the BioCentury This Week PODCAST , BioCentury Editor in Chief Simone Fishburn talks to Washington Editor Steve Usdin about the appointments of Michelle McMurry-Heath as CEO of BIO, Moncef Slaoui as...
Items per page:
1 - 10 of 8131
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

CHMP backs Ebola vaccine, targeted cancer therapies  EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...
BioCentury | May 30, 2020
Finance

Ovarian cancer data help Mersana raise $152M to top off $9B month of follow-ons

Catalyzed by interim data unveiled Wednesday from a Phase I trial of its lead product, Mersana raised $152 million late Thursday to advance its clinical and preclinical antibody-drug conjugates. Mersana Therapeutics Inc. (NASDAQ:MRSN), which also...
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | May 29, 2020
Product Development

CEPI funding fuels Novavax vaccine trial start, ex-U.S. manufacturing land grab

After enrolling the first volunteers in a Phase I/II trial for its COVID-19 vaccine, Novavax acquired a Czech company that will provide manufacturing capacity outside the U.S., helping the biotech to meet its commitment to...
BioCentury | May 28, 2020
Product Development

Daily Chart: TIGIT pipeline heats up

With last week’s data from Genentech, the next-generation checkpoint target TIGIT has started to out-shine its peers. At least 11 TIGIT inhibitors are coming up behind Genentech’s tiragolumab in the pipeline. The Roche unit released...
BioCentury | May 27, 2020
Product Development

FDA takes on COVID-19, plus ASCO’s breakthroughs: a BioCentury podcast

The latest edition of the BioCentury This Week PODCAST covers a lot of ground -- from the new roles FDA’s Janet Woodcock and Peter Marks are taking on in the race to develop COVID-19 countermeasures,...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | May 19, 2020
Politics, Policy & Law

New faces for COVID-19’s next phase, ASCO’s hot topics: a BioCentury podcast

In the latest edition of the BioCentury This Week PODCAST , BioCentury Editor in Chief Simone Fishburn talks to Washington Editor Steve Usdin about the appointments of Michelle McMurry-Heath as CEO of BIO, Moncef Slaoui as...
Items per page:
1 - 10 of 8131